Parker Waichman LLP, a national law firm that protects the rights of victims injured by defective drugs, has filed a lawsuit in Superior Court of New Jersey, Atlantic County Law Division, on behalf of a Maryland woman who suffered two femur fractures after using the bisphosphonate Fosamax. The lawsuit names Merck Sharp & Dohme Corp., Merck & Co. Inc., and other potential manufacturers.
According to the lawsuit the plaintiff began to take Fosamax as prescribed in May 2002, and as a direct result of using Fosamax for a number of years, suffered two femur fractures. The suit says that the defendants failed to warn to users about the risks of Fosamax, including that research says the drug can make bones brittle and vulnerable to fractures.
In 2010, the FDA updated the label on bisphosphonate drugs to warn about the risks of atypical fractures, known as subtrochanteric and diaphyseal femur fractures, of the thigh.
The lawsuit says the plaintiff suffered severe mental and physical pain and suffering, permanent injuries, emotional distress, economic loss due to medical expenses, and living related expenses due to a new lifestyle.